The Role of Microbiome Reprogramming on Liver Fat Accumulation
NCT ID: NCT03914495
Last Updated: 2023-02-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
57 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-21
Study Completion Date
2021-06-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Soluble Fibre Supplementation in NAFLD
NCT05480696
Non-Alcoholic Fatty Liver Disease
Non Alcoholic Steatohepatitis
Hepatic Steatosis
RECRUITING
PHASE2
Supplementation of Probiotics and Fruit Fibre to Patients With Fatty Liver
NCT01423630
Fatty Liver
TERMINATED
NA
A Pilot Study to Explore the Role of Gut Flora in Fatty Liver
NCT04160949
Fatty Liver
WITHDRAWN
Prebiotics in Patients With Non-alcoholic Liver Disease
NCT02642172
Non-alcoholic Fatty Liver Disease
Metabolic Syndrome
COMPLETED
NA
Quality of Life and Nutritional Improvements in Cirrhotic Patients
NCT01842113
Liver Cirrhosis
Hepatic Encephalopathy
Portal Hypertension
TERMINATED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
NAFLD
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DIETARY_SUPPLEMENT
Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
Inulin
Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.
Group Type
ACTIVE_COMPARATOR
Inulin
Intervention Type
DIETARY_SUPPLEMENT
Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inulin
Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
Intervention Type
DIETARY_SUPPLEMENT
Placebo
Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
Intervention Type
DIETARY_SUPPLEMENT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age 35-65 years
2. Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) 5%-30% (+0.5%)
3. Liver stiffness \<3.5 kPa by Magnetic Resonance Elastography (MRE)
4. Body mass index (BMI) 27.5-45 kg/m2
5. Weight stable (weight change of no more than 3 kg +0.5 kg) during the 6 months prior to enrollment
6. For individuals with type 2 diabetes: HbA1c ≥6.5 - \<9.5%. If taking allowable diabetes medications, HbA1c can be below 6.5%.
7. Fasting triglycerides 400 mg/dL (4.5 mmol/L)
8. Able to speak and understand written and spoken English
9. Understands the procedures and agrees to participate by giving written informed consent
10. Willing and able to comply with scheduled study days, laboratory tests, and other study procedures
2. Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) 5%-30% (+0.5%)
3. Liver stiffness \<3.5 kPa by Magnetic Resonance Elastography (MRE)
4. Body mass index (BMI) 27.5-45 kg/m2
5. Weight stable (weight change of no more than 3 kg +0.5 kg) during the 6 months prior to enrollment
6. For individuals with type 2 diabetes: HbA1c ≥6.5 - \<9.5%. If taking allowable diabetes medications, HbA1c can be below 6.5%.
7. Fasting triglycerides 400 mg/dL (4.5 mmol/L)
8. Able to speak and understand written and spoken English
9. Understands the procedures and agrees to participate by giving written informed consent
10. Willing and able to comply with scheduled study days, laboratory tests, and other study procedures
Exclusion Criteria
Acute or chronic medical conditions or medication that would contraindicate the participation in the research testing or could potentially affect metabolic function including, but not limited to:
1. Diagnosis of type 1 diabetes mellitus
2. Insulin use
3. Change within 3 months of screening of any medication used to treat insulin resistance or type 2 diabetes
4. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males within the previous 6 months (1 drink = 5 ounces \[150 mL\] of wine, 12 ounces \[360 mL\] of beer, or 1.5 ounces \[45 mL\] of hard liquor)
5. A total score of 8 on the Alcohol Use Disorders Identification Test (AUDIT) questionnaire, indicating harmful or hazardous alcohol consumption
6. Clinical evidence of hepatic decompensation, including, but not limited to esophageal varices, ascites, or hepatic encephalopathy
7. Evidence of other forms of chronic liver disease (including laboratory tests and confirmed with a single repeat, if needed):
* Hepatitis B virus: defined by presence of hepatitis B surface antigen
* Hepatitis C virus: As defined by a clinical history of previous diagnosis of Hepatitis C (treated or untreated) or a positive Hepatitis C antibody.
* Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or overlap syndrome
* Alcoholic liver disease
* Known diagnosis of hemochromatosis
* Prior known drug-induced liver injury
* Known or suspected hepatocellular carcinoma or other liver cancer
* History of liver transplant, current placement on a liver transplant list, or current model of end-stage liver disease (MELD) score \>12
* Histological presence of cirrhosis on a prior biopsy
8. Bleeding disorders
9. Acute or chronic infections
10. Severe asthma or chronic obstructive pulmonary disease
11. Renal insufficiency or nephritis
12. Thyroid dysfunction (suppressed TSH, elevated TSH \<10 µIU/ml if symptomatic or elevated TSH \>10 µIU/ml if asymptomatic)
13. Uncontrolled hypertension (BP \>160 mmHg systolic or \>100 mmHg diastolic)
14. Prior or planned bariatric surgery
15. Gastrointestinal disorders including: inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis.
16. Participants with intolerance to soluble fiber, sucralose or erythritol.
17. A positive urine drug test for illicit drugs
18. History of major depression within \<5 years from screening or which, in the opinion of a medical investigator, will impact the participant's ability to complete the study.
19. History of eating disorders
20. History of Cushing's disease or syndrome
21. Untreated or inadequately controlled hypo- or hyperthyroidism
22. Active rheumatoid arthritis or other inflammatory rheumatic disorder
23. Pregnant or nursing females or females less than 6 months postpartum from the scheduled date of collection
24. Nicotine use within the past 3 months
25. Had major surgery within 4 weeks prior to Screening.
26. Anemia (hemoglobin \<12 g/dl in men, \<11 g/dl in women) during screening
27. Participation in studies involving investigational drug(s) within 30 days prior to Screening
28. History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, presence of cardiac pacemaker, implanted cardiac defibrillator)
29. Human Immunodeficiency Virus (HIV) infection defined as: previous diagnosis of HIV infection, history of positive screening or quantitative HIV testing; positive HIV screen
30. Any malignancy not considered cured, except basal cell carcinoma and squamous cell carcinoma of the skin (a participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years)
31. Use of drugs historically associated with non-alcoholic fatty liver disease (NAFLD) for 1 month in the previous year prior to Screening; examples include: amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, other known hepatotoxins
32. Participants who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos
33. Unable to participate in MR assessments due to physical limitations or equipment tolerances (e.g., MRI bore size and 500-pound weight limit) based on Investigator's judgment at screening
34. Any person with history of severe claustrophobia or unable to lie still within the environment of the MRI scanner or unable maintain a breath hold for the required period to acquire images without mild sedation/treatment with an anxiolytic
35. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Screening (participants may not donate blood any time during the study, through the final study day)
36. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study days
1. Diagnosis of type 1 diabetes mellitus
2. Insulin use
3. Change within 3 months of screening of any medication used to treat insulin resistance or type 2 diabetes
4. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males within the previous 6 months (1 drink = 5 ounces \[150 mL\] of wine, 12 ounces \[360 mL\] of beer, or 1.5 ounces \[45 mL\] of hard liquor)
5. A total score of 8 on the Alcohol Use Disorders Identification Test (AUDIT) questionnaire, indicating harmful or hazardous alcohol consumption
6. Clinical evidence of hepatic decompensation, including, but not limited to esophageal varices, ascites, or hepatic encephalopathy
7. Evidence of other forms of chronic liver disease (including laboratory tests and confirmed with a single repeat, if needed):
* Hepatitis B virus: defined by presence of hepatitis B surface antigen
* Hepatitis C virus: As defined by a clinical history of previous diagnosis of Hepatitis C (treated or untreated) or a positive Hepatitis C antibody.
* Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, or overlap syndrome
* Alcoholic liver disease
* Known diagnosis of hemochromatosis
* Prior known drug-induced liver injury
* Known or suspected hepatocellular carcinoma or other liver cancer
* History of liver transplant, current placement on a liver transplant list, or current model of end-stage liver disease (MELD) score \>12
* Histological presence of cirrhosis on a prior biopsy
8. Bleeding disorders
9. Acute or chronic infections
10. Severe asthma or chronic obstructive pulmonary disease
11. Renal insufficiency or nephritis
12. Thyroid dysfunction (suppressed TSH, elevated TSH \<10 µIU/ml if symptomatic or elevated TSH \>10 µIU/ml if asymptomatic)
13. Uncontrolled hypertension (BP \>160 mmHg systolic or \>100 mmHg diastolic)
14. Prior or planned bariatric surgery
15. Gastrointestinal disorders including: inflammatory bowel disease or malabsorption, swallowing disorders, suspected or known strictures, fistulas or physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's disease or diverticulitis.
16. Participants with intolerance to soluble fiber, sucralose or erythritol.
17. A positive urine drug test for illicit drugs
18. History of major depression within \<5 years from screening or which, in the opinion of a medical investigator, will impact the participant's ability to complete the study.
19. History of eating disorders
20. History of Cushing's disease or syndrome
21. Untreated or inadequately controlled hypo- or hyperthyroidism
22. Active rheumatoid arthritis or other inflammatory rheumatic disorder
23. Pregnant or nursing females or females less than 6 months postpartum from the scheduled date of collection
24. Nicotine use within the past 3 months
25. Had major surgery within 4 weeks prior to Screening.
26. Anemia (hemoglobin \<12 g/dl in men, \<11 g/dl in women) during screening
27. Participation in studies involving investigational drug(s) within 30 days prior to Screening
28. History or presence of cardiovascular disease (unstable angina, myocardial infarction or coronary revascularization within 6 months, presence of cardiac pacemaker, implanted cardiac defibrillator)
29. Human Immunodeficiency Virus (HIV) infection defined as: previous diagnosis of HIV infection, history of positive screening or quantitative HIV testing; positive HIV screen
30. Any malignancy not considered cured, except basal cell carcinoma and squamous cell carcinoma of the skin (a participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years)
31. Use of drugs historically associated with non-alcoholic fatty liver disease (NAFLD) for 1 month in the previous year prior to Screening; examples include: amiodarone, methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used for hormone replacement, anabolic steroids, valproic acid, other known hepatotoxins
32. Participants who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos
33. Unable to participate in MR assessments due to physical limitations or equipment tolerances (e.g., MRI bore size and 500-pound weight limit) based on Investigator's judgment at screening
34. Any person with history of severe claustrophobia or unable to lie still within the environment of the MRI scanner or unable maintain a breath hold for the required period to acquire images without mild sedation/treatment with an anxiolytic
35. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Screening (participants may not donate blood any time during the study, through the final study day)
36. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study days
Minimum Eligible Age
35 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AdventHealth Translational Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen Corbin, PhD
Role: PRINCIPAL_INVESTIGATOR
Study Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Translational Research Institute for Metabolism and Diabetes
Orlando, Florida, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.
Reference Type
BACKGROUND
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.
Reference Type
BACKGROUND
Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519-23. doi: 10.1126/science.1204265.
Reference Type
BACKGROUND
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30.
Reference Type
BACKGROUND
Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. FEBS Lett. 2017 Oct;591(19):3061-3088. doi: 10.1002/1873-3468.12742. Epub 2017 Jul 25.
Reference Type
BACKGROUND
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
Reference Type
BACKGROUND
Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, Calabria S, Scaturro G, Mantovani A, Zoppini G, Turcato E, Maggioni AP, Arcaro G, Targher G. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018 Aug 15;265:162-168. doi: 10.1016/j.ijcard.2018.04.129. Epub 2018 May 2.
Reference Type
BACKGROUND
Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010 Jul;105(7):1567-73. doi: 10.1038/ajg.2010.18. Epub 2010 Feb 9.
Reference Type
BACKGROUND
Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15430-5. doi: 10.1073/pnas.0904944106. Epub 2009 Aug 24.
Reference Type
BACKGROUND
Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016 Aug;65(8):1136-50. doi: 10.1016/j.metabol.2015.09.017. Epub 2015 Sep 25.
Reference Type
BACKGROUND
Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.
Reference Type
BACKGROUND
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29. No abstract available.
Reference Type
BACKGROUND
Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12511-6. doi: 10.1073/pnas.0601056103. Epub 2006 Aug 8.
Reference Type
BACKGROUND
Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 May 8;7(1):1529. doi: 10.1038/s41598-017-01751-y.
Reference Type
BACKGROUND
Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gerard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-94. doi: 10.1136/gutjnl-2012-303816. Epub 2012 Nov 29.
Reference Type
BACKGROUND
Kaden-Volynets V, Basic M, Neumann U, Pretz D, Rings A, Bleich A, Bischoff SC. Lack of liver steatosis in germ-free mice following hypercaloric diets. Eur J Nutr. 2019 Aug;58(5):1933-1945. doi: 10.1007/s00394-018-1748-4. Epub 2018 Jun 20.
Reference Type
BACKGROUND
De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014 May;59(5):1738-49. doi: 10.1002/hep.26695. Epub 2014 Feb 25.
Reference Type
BACKGROUND
Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, Sanyal AJ, Heuman DM, Carl D, Zhou H, Liu R, Wang X, Yang J, Jiao C, Herzog J, Lippman HR, Sikaroodi M, Brown RR, Bajaj JS. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology. 2016 Oct;64(4):1232-48. doi: 10.1002/hep.28696. Epub 2016 Jul 29.
Reference Type
BACKGROUND
Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015 Mar;29(3):1043-55. doi: 10.1096/fj.14-259515. Epub 2014 Dec 2.
Reference Type
BACKGROUND
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.tri-md.org
Webpage for Translational Research Institute for Metabolism and Diabetes
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1312439
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT01791959
COMPLETED
PHASE2/PHASE3
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
NCT04175392
TERMINATED
PHASE1/PHASE2
Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis
NCT05821010
RECRUITING
PHASE2
Histological Improvement of NASH With Prebiotic
NCT03184376
COMPLETED
NA
The Effect of a Probiotic on Hepatic Steatosis
NCT00099723
TERMINATED
PHASE1
Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic
NCT04100109
WITHDRAWN
NA
Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers
NCT03513523
COMPLETED
NA
Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease
NCT02690792
COMPLETED
NA
Effects of Carnitine Supplementation on Liver and Muscle
NCT03439917
COMPLETED
NA
Healthy Volunteer Short Chain Fatty Acid Study
NCT05254340
TERMINATED
NA
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
NCT01466894
WITHDRAWN
PHASE2
A Feasibility Trial of OCM Supplements for the Treatment of NAFLD
NCT05720702
COMPLETED
EARLY_PHASE1
The Effect of Probiotics on Non Alcoholic Fatty Liver Disease
NCT00808990
TERMINATED
PHASE1
A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity
NCT02787668
COMPLETED
NA
Effects of Bacillus Coagulans on Liver and Gut Microbiota Function in NAFLD
NCT05635474
UNKNOWN
NA
Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.
NCT01696487
COMPLETED
NA
Synbiotics Interventions for Managing Cirrhosis and Its Complications
NCT05687409
COMPLETED
PHASE4
Evaluation of Intestinal Microbiome in Obese Kids
NCT00816296
WITHDRAWN
Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study
NCT02366052
COMPLETED
PHASE2
Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
NCT05897606
COMPLETED
PHASE1
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
NCT03867487
NOT_YET_RECRUITING
PHASE2
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04073368
COMPLETED
NA
Vitamin E Dosing Study
NCT04801849
COMPLETED
PHASE2
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
NCT04147936
COMPLETED
NA
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
NCT00364689
TERMINATED
PHASE3